tirzepatide maximum weight loss surmount trials for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial SURMOUNT-5: Tirzepatide shows superior weight

Symptoms of bipolar disorder, such as mania or hypomania, more energy than usual, impulsive behaviors, racing thoughts, and reduced need for sleep

Expectations should emphasize body composition changes, metabolic improvements (blood glucose, lipids, inflammation markers), and behavioral shifts rather than dramatic weight reduction

He has received unrestricted research grants from Celgene/BMS and Novartis

Important Safety Notes: Never take two doses within 48 hours of each other Contact healthcare providers if missing doses for more than 2 weeks Monitor blood sugar levels more frequently after missing doses Resume regular weekly schedule after addressing missed dose Disclaimer: The FDA does not approve compounded medications for safety, quality, or manufacturing